Clinical trial of gefitinib tablets combined with Kanglaite capsules in the treatment of stage ⅢB/Ⅳ non-small cell lung cancer
10.13699/j.cnki.1001-6821.2017.17.006
- VernacularTitle:吉非替尼片联合康莱特胶囊治疗ⅢB/Ⅳ期非小细胞肺癌的临床研究
- Author:
Jun-Yan WANG
1
;
Su-Ju WEI
;
Lei HONG
;
Fan ZHANG
;
Cheng-Yuan LIU
;
Yan KONG
Author Information
1. 河北医科大学第四医院肿瘤内科
- Keywords:
Kanglaite capsule;
gefitinib tablet;
non-small cell lung cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(17):1631-1633
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of gefitinib tablets combined with Kanglaite capsules in the treatment of stage Ⅲ B/Ⅳ non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) sensitive mutations.Methods Eighty patients of stage Ⅲ B/Ⅳ NSCLC with EGFR sensitive mutations were randomly divided into control group and treatment group with 40 cases per group.Control group was given gefitinib 250 mg · d-1,qd,oral.Treatment group received Kanglaite capsule 2.7 mg,qid,oral,on the basis of control group.Two groups were treated to tumor progression or intolerant.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in control and treatment groups were 17.50％ (7/40 cases) and 7.50％ (3/40 cases),disease control rates (DCR) in control and treatment groups were 92.50％ (37/40 cases) and 87.50％ (35/40 cases),progress free survival in control and treatment groups were 17.7 months and 16.3 months,the differences were statistically significant (all P ＞ 0.05).The adverse drug reactions in treatment group were based on diarrhea,rash and loss of appetite,which in control group were based on diarrhea,rash and nausea.The incidences of adverse drug reactions in treatment and control groups were 60.00％ and 85.00％ with significant difference (P ＜ 0.05).Conclusion Gefitinib tablet combined with Kanglaite capsule can reduce the incidence of adverse drug reaction,and maybe extend the progress free survival.
